Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet–visible high-performance liquid chromatography

由 Chin, David L., Lum, Bert L., Sikic, Branimir I.
出版 2002

A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions

由 Xiao, Jim J., Chen, Jiyun S., Lum, Bert L., Graham, Richard A.
發表在 Anticancer Drugs (2017)

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors:...

由 Xu, Na, Redfern, Charles H., Gordon, Michael, Eppler, Stephen, Lum, Bert L., Trudeau, Caroline
發表在 Cancer Chemother Pharmacol (2014)

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

由 Lu, Dan, Lu, Tong, Stroh, Mark, Graham, Richard A., Agarwal, Priya, Musib, Luna, Li, Chi-Chung, Lum, Bert L., Joshi, Amita
發表在 Cancer Chemother Pharmacol (2016)

A Phase I/II Trial of Trastuzumab plus Erlotinib in Metastatic HER2-Positive Breast Cancer: A Dual ErbB Targeted Approach

由 Britten, Carolyn D., Finn, Richard S., Bosserman, Linda D., Wong, Steven G., Press, Michael F., Malik, Mubashira, Lum, Bert L., Slamon, Dennis J.
發表在 Clin Breast Cancer (2009)

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive...

由 Quartino, Angelica L., Hillenbach, Carina, Li, Jing, Li, Hanbin, Wada, Russell D., Visich, Jennifer, Li, Chunze, Heinzmann, Dominik, Jin, Jin Y., Lum, Bert L.
發表在 Cancer Chemother Pharmacol (2015)

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

由 Quartino, Angelica L., Li, Hanbin, Jin, Jin Y., Wada, D. Russell, Benyunes, Mark C., McNally, Virginia, Viganò, Lucia, Nijem, Ihsan, Lum, Bert L., Garg, Amit
發表在 Cancer Chemother Pharmacol (2017)

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

由 Graham, Richard A, Hop, Cornelis E C A, Borin, Marie T, Lum, Bert L, Colburn, Dawn, Chang, Ilsung, Shin, Young G, Malhi, Vikram, Low, Jennifer A, Dresser, Mark J
出版 2012

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

由 Graham, Richard A., Lum, Bert L., Cheeti, Sravanthi, Jin, Jin Yan, Jorga, Karin, Von Hoff, Daniel D., Rudin, Charles M., Reddy, Josina C., Low, Jennifer A., LoRusso, Patricia M.
出版 2011

Phase I Study of Valspodar (PSC-833) with Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report from the Children’s Oncology Group

由 O’Brien, Maureen M., Lacayo, Norman J., Lum, Bert L., Kshirsagar, Smita, Buck, Steven, Ravindranath, Yaddanapudi, Bernstein, Mark, Weinstein, Howard, Chang, Myron N., Arceci, Robert J., Sikic, Branimir I., Dahl, Gary V.
出版 2010

Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey

由 Zuch de Zafra, Christina L, Ashkenazi, Avi, Darbonne, Walter C, Cheu, Melissa, Totpal, Klara, Ortega, Shirley, Flores, Heather, Walker, Mark D, Kabakoff, Bruce, Lum, Bert L, Mounho-Zamora, Barbara J, Marsters, Scot A, Dybdal, Noël O
發表在 Cell Death Dis (2016)